[March 03, 2015]

ArtVentive Medical Group, Inc. Announces First Use of ArtVentive EOS™ in the United States

ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today the first use of its Endoluminal Occlusion System (EOS™) in the United States at The Johns Hopkins Hospital in Baltimore, MD, where Dr.'s Kelvin Hong and Anobel Tamrazi performed a splenic artery occlusion using the ArtVentive EOS™ device.

"The EOS™ device performed very well in a challenging clinical setting. We achieved immediate occlusion of the target vessel and concluded the case in rapid fashion," stated Dr. Kelvin Hong, Division Chief of Vascular and Interventional Radiology at Johns Hopkins Medical Institutions. "The unique ability to visualize the EOS™ device prior to deployment provides confidence in the placement of the device and enables precise delivery."

Jim Graham, ArtVentive's Chief Executive Officer, commented, "Following our recent FDA clearance, this is an important milestone for our organization and a statement to the tremendous efforts of our entire team over several years. We are excited to bring this proprietary technology to additional centers as we expand our commercialization efforts in the U.S., as well as in Europe."

Leon Rudakov, PhD, President and Chief Technology Officer, stated, "The EOS™ platform allows physicians to treat their patients effectively and efficiently. We believe the unique ability of the EOS™ device to provide a high level of visualization and immediate oclusion enhances operator control and confidence during the procedure. These design characteristics allow physicians to provide a higher level of treatment and heightens the ability to efficiently address the clinical needs of their patients."

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices.

The ArtVentive EOS™ platform is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body's vascular system and organ network. The ArtVentive EOS™ is designed to serve as an alternative to major surgery in certain cases. This technological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant, unaddressed health issues.

The ArtVentive EOS™ proprietary technology platform provides a foundation for future innovation and has the potential to address indications in several clinical areas, including peripheral and neurological vascular disorders, women's health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.

More information about ArtVentive can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company's current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company's control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company's ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company's future results to differ materially from any forward-looking statements, see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.

[ Back To TMCnet.com's Homepage ]